Fol. Biol. 2004, 50, 120-130
Interleukin-2 Therapy of Cancer
The aim of this review is to evaluate the results of IL-2 therapy of cancer two decades after the first experiments and to discuss whether and which results of local, systemic and adjuvant IL-2 therapy in preclinical models can be translated into clinics. The attention is also focused on the development and utilization of the IL-2 gene-modified tumour vaccines for therapeutic purposes. The prospects and limitations of both, IL-2 therapy and IL-2 gene therapy are discussed.
Funding
The work of the author's laboratory discussed here was supported by grant No. NC/7148-3 from the Grant Agency of the Ministry of Health of the Czech Republic; No. 301/04/0492 from the Grant Agency of the Czech Republic; No. A5052203 from the Grant Agency of the Academy of Sciences of the Czech Republic and by the League Against Cancer, Prague.
References
Copyright
This is an open-access article distributed under the terms of the Creative Commons Attribution License.